Switching from etelcalcetide to evocalcet in hemodialysis patients with secondary hyperparathyroidism

Switching from etelcalcetide to evocalcet in hemodialysis patients with secondary hyperparathyroidism - Switching from etelcalcetide to evocalcet

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033856

Enrollment

Registered

2018-09-01

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism

Interventions

Evocalcet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Receiving etelcalcetide

Exclusion criteria

Exclusion criteria: Receiving hemodialysis less than three months

Design outcomes

Primary

Measure	Time frame
Proportion of patients with mean intact PTH levels during weeks 20-24 of 60-240 pg/ml.	—

Secondary

Measure	Time frame
Proportion of patients with >=30% reduction from baseline in mean intact PTH levels during weeks 20-24; changes from baseline in serum calcium, phosphorus, intact PTH, and alkaline phosphatase; and adverse events.	—

Countries

Japan

Contacts

Public ContactHiroo Takahashi

Jinken Clinic Not applicable

htp911@cocoa.ocn.ne.jp046-231-8151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026